Table 1.
Comparison of the phase 3 clinical trials involving patients with advanced-stage HCC (BCLC-C) and those with intermediate-stage HCC (BCLC-B) who progressed on TACE
| Asia Pacific |
SHARP |
REFLECT |
RESORCE |
CELESTIAL |
REACH-2 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sorafenib (n = 150) | Placebo (n = 76) | Sorafenib (n = 299) | Placebo (n = 303) | lenvatinib (n = 478) | sorafenib (n = 476) | Regorafenib (n = 379) | Placebo (n = 194) | cabozantinib (n = 470) | Placebo (n = 237) | ramucirumab (n = 197) | Placebo (n = 95) | |
| BCLC-B | 7 (5%) | 3 (4%) | 54 (18%) | 51 (17%) | 104 (22%) | 92 (19%) | 53 (14%) | 22 (11%) | 72 (15%) | 37 (16%) | 34 (17%) | 20 (21%) |
| BCLC-C | 143 (95%) | 73 (96%) | 244 (82%) | 252 (83%) | 374 (78%) | 384 (81%) | 325 (86%) | 172 (89%) | 398 (85%) | 200 (84%) | 163 (83%) | 75 (79%) |